Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Aclaris Therapeutics (ACRS) reported a Q3 loss of $0.11 per share, missing the Zacks Consensus Estimate of a $0.08 loss. This is an improvement from the $0.41 loss per share a year ago.
November 06, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aclaris Therapeutics reported a Q3 loss of $0.11 per share, missing analyst expectations of a $0.08 loss. However, this is an improvement from the previous year's $0.41 loss per share.
The reported loss per share was worse than expected, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100